StockData
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. (SPRO) stock

SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3045% below fair value
$0.87−0.03 (-3.03%)

Close on Nov 18, 2026Market cap $50.90MP/E 21.9Yield –

Spero Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Spero Therapeutics's pe ratio was 25.5× on Nov 11, 2026, against 19.0× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202625.5×+11.2
2025Jan 31, 202514.3×−2.9
2024Dec 31, 202417.2×–

More Spero Therapeutics figures

See a number that looks wrong?